---
schema_version: "secwatch.filing_event.v1"
accession: "0001815776-25-000017"
form_type: "8-K"
ticker: "LENZ"
cik: "0001815776"
company_name: "LENZ Therapeutics, Inc."
filed_at: "2025-03-19T23:59:59+00:00"
generated_at: "2026-05-24T12:08:36.850863+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# LENZ Therapeutics reports FY2024 net loss $49.8M; LNZ100 PDUFA set for Aug 8, 2025

## Summary
- FDA accepted NDA for LNZ100 (presbyopia); PDUFA target action date Aug 8, 2025; no advisory committee planned.
- Cash, cash equivalents & marketable securities $209.1M; cash runway expected to post-launch positive operating cash flow.
- FY2024 net loss $49.8M ($2.34/share) vs FY2023 net loss $70.0M ($35.71/share).
- R&D expenses fell to $29.8M in FY2024 from $59.5M in FY2023 as Phase 3 CLARITY study concluded.
- SG&A expenses rose to $28.8M in FY2024 from $12.9M in FY2023 due to pre-commercial buildout for potential LNZ100 launch.

## SEC filing metadata
- accession: 0001815776-25-000017
- form_type: 8-K
- ticker: LENZ
- cik: 0001815776
- company_name: LENZ Therapeutics, Inc.
- filed_at: 2025-03-19T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815776/000181577625000017/0001815776-25-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815776/000181577625000017/lenz-20250319.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001815776-25-000017
- JSON: https://secwatch.observer/filing/0001815776-25-000017.json
- Plain text: https://secwatch.observer/filing/0001815776-25-000017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.